English
/
中文
HOME
Home
WHO WE ARE
Nav
WHAT WE DO
Nav
INVESTORS
Nav
PIPELINE
Nav
NEWS
Nav
CAREERS
Nav
CONTACT US
Nav
HISTORY
LEADERSHIP
ADVISORS
BOARD OF DIRECTORS
BETTER AFFORDABLE
MEDICINES FOR PATIENTS
IN CHINA AND BEYOND
We are a growing Chinese pharmaceutical company developing therapeutics for patients in China and beyond.
The first program is the IL-17A mAb licensed from Janssen. We have attracted experienced minds in drug reaserch and development.
Our team brings together scientists from China, the US and Europe. Our current focus is therapeutics for auto-immune disease and cancer.
Pipeline
Investors
About Fontacea
more>>
06/24
2020
Fontacea supports Guzhang through alleviating poverty
It is the traditional virtue of the Chinese nation to help the needy and worship virtue.A group of local products from p...
02/10
2020
Mr Yanliang Chu, chairman of Fontacea, signed Dr David Brooks as business consultant in USA
Mr Yanliang Chu, chairman of Fontacea, signed Dr David Brooks as business consultant in USA starting from Feb 10th, 202...
12/23
2019
Mr Yanliang Chu, Chairman of Fontacea, signed Dr Timothy P. Coogan as the Medicine Safety Consultant
Mr Yanliang Chu, chairman of Fontacea, signed Dr Timothy P. Coogan as the Medicine Safety Consultant in USA on Dec 21,20...
12/11
2019
Senior leaders attended "Innovative Medicine Investment Seminar"
Senior leaders of Fontacea, Yanliang Chu, Xiaoli Chai, and Liang Li, attended the Innovative Medicine Investment seminar...
09/10
2019
Shandong Fontacea is licensed for anti-IL17A monoclonal antibody from Janssen
08/12
2019
Yanliang Chu, welcomes Mark Winnett as Management Consultant to Fontacea
Mr Yanliang Chu, chairman of Shandong Fontacea Pharmaceutical Co., Ltd., (“Fontacea”, based in Jinan, Shandong), and Mr ...
NEWS & EVENTS
Better affordable medicines for patients in China and beyond.
Contact US ▶